NPM1 and acute myeloid leukemia: This prognostic stratification is still under debate and especially patients with FLT3-ITDlow lacking a concomitant NPM1 mutation are difficult to monitor for minimal residual disease (MRD) and several studies demonstrate a clinical benefit of alloHSCT in first remission of AML patients harboring FLT3-ITD independently of the AR of FLT3-ITD [7,8].